Cyclosporin is a cyclic peptide of 11 aminoacids. First isolated as an antifungal agent, this substance has proved to be a powerful immunosuppressive agent in the prevention of graft rejection after the transplantation of solid organs or bone marrow and in the control of autoimmune diseases.' Its action is different from that of other immunosuppressive drugs in that it is not an alkylating or antimitotic agent, but rather selectively affects T-lymphocytes and inhibits the production and secretion of the helper cell-factor interleukin 2 and other lymphokinins.2 Its adverse effects are also different from those of other immunosuppressive drugs including dose related nephrotoxicity and hepatoxicity.34
It has been shown recently in rats that chronic administration of cyclosporin causes severe degranulation and hydropic degeneration of islet B-cells5 and a decrease in insulin content and secretion.6 7 Prostaglandins have attracted great interest because of their ability to prevent damage to the stomach from contact necrosis induced by a variety of noxious agents,8 to prevent liver necrosis caused by agents such as carbon tetrachloride,9 galacto-samine,'°and ethanoll' and to decrease the severity of diet induced acute pancreatitis in mice. ' experienced a similar increase in weight during the test period (Fig. 1 ).
RELATIONSHIP BETWEEN INTRAGASTRAL APPLIED CYCLOSPORIN AND BLOOD CONCENTRATIONS OF CYCLOSPORIN IN GROUPS WITH OR WITHOUT SUBCUTANEOUS TREATMENT WITH RIOPROSTIL
Blood levels were taken 18-20 hours after the last application of cyclosporin. Subcutaneous application of Rioprostil did not significantly influence the blood levels of cyclosporin (Table 1) .
EFFECTS OF CYCLOSPORIN AND RIOPROSTIL ON GLUCOSE-DEPENDENT INSULIN SECRETION
Five milligrams per kilogram of cyclosporin applied intragastrically caused an almost 50% reduction in insulin release (Fig. 2 , Table 2 ). The effect of 10 mg/ kg was not significantly different (Fig. 3, Table 2 ). A significant further reduction was found with the dosage of 20 mg/kg cyclosporin (Fig. 4, Table 2 ). Subcutaneous injection of Rioprostil at a dosage of 7.5 [sg/kg twice daily did not influence insulin secretion in controls (Fig. 5 , Table 2 ). This dose of Rioprostil could almost completely protect the Bcells from the noxious effect of 5 mg/kg cyclosporin (Fig. 2, Table 2 ). This cytoprotective effect was less, but still significantly pronounced at 10 mg/kg cyclosporin and 20 mg/kg (Figs 3 and 4, Table 2 ). To exclude the possibility that Rioprostil would affect peak levels of cyclosporin in the blood by interfering with absorption from the gut, cyclosporin was applied intragastrically in a bolus of 5 mg/ kg in the presence or absence of 15 [tg/kg Rioprostil.
We found that Rioprostil has no significant effect on the blood concentrations of cyclosporin (Fig. 6 ).
Discussion
The present study confirms previous findings that cyclosporin causes severe impairment of glucose dependent insulin secretion. '7 In contrast with previous studies the doses which were used neither affected animal weight gain, nor produced light microscopic changes in the pancreas, nor were they nephrotoxic. Glucose dependent insulin secretion and its potentiation by CCK 8, however, were already markedly reduced. At the lowest dose of cyclosporin (5 mg/kg), insulin secretion was impaired by almost 50% after eight days of treatment. This noxious effect of cyclosporin could be completely prevented by the parenteral administration of Rioprostil, a PGE1 analogue in a dosage of 7.5 [tg/kg twice daily. The impairment of insulin secretion with doses which were not nephrotoxic suggests that the pancreatic B-cells of rat are more sensitive to cyclosporin toxicity than kidney cells.
The ability to show the beneficial effects of prostaglandins depends on several factors. One is that treatment of the prostaglandins before the introduction of noxious agents is essential in order to gain the most beneficial effects.'5 This was the reason for starting with the parenteral administration of Rioprostil before the intragastral application of cyclosporin. It has previously been shown in the rat stomach that the antiulcer and cytoprotective activity of Rioprostil sets in rapidly, and it is seen after only four minutes' pretreatment. 16 Whether it is necessary or better to administer the prostaglandin analogue twice daily and to start pretreatment four days before applying cyclosporin will be the subject of further study.
Another factor which determines cytoprotective ability is its dependency on the dosage of noxious agents.'5 This is clearly shown in the present study, where the greatest beneficial effect of Rioprostil is seen with the lowest dose of cyclosporin, resulting almost in complete protection. The cytoprotective effect is less, but still significantly pronounced at higher doses. Although no microscopic changes could be observed in the pancreas, even with the highest dose of cyclosporin, this finding probably reflects the extent of the functional derangement of insulin secretion.
Reports which have suggested that prostaglandins can prevent diet induced pancreatitis and liver necrosis caused by various agents extend the concept of prostaglandin mediated cytoprotection to nonmucous secreting organs. The mechanism which is responsible for this cytoprotective action still has to be determined. There has been speculation that prostaglandins may act by stabilising cell membranes,8 that cytoprotection may be related to lysosomal stability," or that it may be related to stimulation of the RES by increasing macrophage migration into the pancreas and subsequent phagocytosis of cell debris.'5 The evidence that Rioprostil markedly decreases damage to the pancreas against cyclosporin toxicity could have therapeutic implications for man. It remains to be determined, however, whether the immunosuppressive effect of cyclosporin will be influenced by Rioprostil. 
